Trials / Completed
CompletedNCT00063427
Study Evaluating MAC-321 in Colorectal Cancer
A Phase 2, Open-Label Study of MAC-321 Administered Intravenously as a Single Agent for the Treatment of Advanced Colorectal Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Assess the clinical activity of MAC-321 administered IV as a second-line or third-line antineoplastic agent to subjects with advanced colorectal cancer. Clinical activity will be assessed by determining the percentage of subjects exhibiting an objective response (complete plus partial responses). Tumor response will be assessed following modified Response Evaluation Criteria in Solid Tumors (RECIST) guidelines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MAC-321 |
Timeline
- Primary completion
- 2004-02-01
- Completion
- 2004-02-01
- First posted
- 2003-06-27
- Last updated
- 2009-08-21
Source: ClinicalTrials.gov record NCT00063427. Inclusion in this directory is not an endorsement.